Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Ocelot Bio Appoints Lise Kjems, M.D., Ph.D., as Chief Medical Officer
Ocelot Bio, a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat […]
Ochre Bio Strengthens Leadership Team and Board of Directors with Liver Disease Translational Expertise
Ochre Bio, an innovator in chronic liver disease medicine development, is pleased to announce the […]
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Arrowhead Pharmaceuticals today announced that the first patient has been dosed in Takeda’s Phase 3 […]
Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease
Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more